Apellis Pharmaceuticals Azioni (NASDAQ: APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Azioni

APELLIS PHARMACEUTICALS INC

Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals Inc

Raymond James analyst Ryan Deschner downgrades Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) from Strong Buy to Outperform and lowers the price target from $75 to $52.

News

Downgrades

Price Target

Analyst Ratings

APLS

Raymond James Downgrades Apellis Pharmaceuticals to Outperform, Lowers Price Target to $52

B of A Securities analyst Tazeen Ahmad downgrades Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) from Buy to Neutral and lowers the price target from $41 to $23.

B of A Securities Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $23

RBC Capital analyst Luca Issi maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $21 to $18.

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $18

Scotiabank analyst Greg Harrison maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $28 to $20.

Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $20

Wells Fargo analyst Derek Archila maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight and lowers the price target from $30 to $26.

Wells Fargo Maintains Equal-Weight on Apellis Pharmaceuticals, Lowers Price Target to $26

Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $55 to $47.

Baird Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $47

Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Buy and lowers the price target from $40 to $29.

Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $29

U.S. stock futures were higher this morning, with the Dow futures gaining over 300 points on Wednesday.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) fell sharply in today's pre-market trading after the company <a href="https://www.benzinga.com/quote/SRPT/earnings">reported a first-quarter adjusted EPS miss.</a>
Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. Quarterly revenue came in at $744.86 million, which beat the consensus estimate of $683.36 million.
Sarepta Therapeutics lowered its fiscal 2025 revenue to a new range of $2.3 billion to $2.6 billion.
Sarepta Therapeutics shares tumbled 20.6% to $37.10 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Vestis Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) fell 25.7% to $6.47 in pre-market trading after the company reported worse-than-expected quarterly financial results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) fell 16.2% to $43.09 in pre-market trading after the company issued second-quarter sales guidance below estimates.</li>
<li>Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) dipped 13.6% to $16.53 in pre-market trading following first-quarter results.</li>
<li>Revolve Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVLV#NYSE">RVLV</a>) fell 10.8% to $16.90 in today's pre-market trading after the company reported downbeat quarterly sales.</li>
<li>The Hackett Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) dipped 8.9% to $23.69 in pre-market trading after the company issued weak outlook for the second quarter.</li>
<li>RXO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) fell 7.6% to $12.70 in pre-market trading.</li>
<li>Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) dipped 7% to $56.94 in pre-market trading after the company postponed its Investor Day amid uncertainty.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) declined 6.5% to $98.06 in pre-market trading after the company posted downbeat first-quarter results and lowered its FY25 forecast.</li>
<li>Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) fell 5.7% to $47.54 in pre-market trading following weaker-than-expected quarterly earnings.</li>
<li>Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) dipped 5.3% to $86.00 in pre-market trading following downbeat quarterly sales.  </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANET

HCKT

LNTH

MRCY

MRVL

RVLV

SRPT

UPST

VSTS

Sarepta Therapeutics, Mercury Systems, Arista Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Apellis Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Biotech

Guidance

Health Care

General

Apellis Pharmaceuticals' Cash And Cash Equivalents Of $358.4M As Of March 31, 2025; Projected Revenues And Cash Expected To Be Sufficient To Fund Operations To Profitability

Earnings

Apellis Pharmaceuticals Q1 EPS $(0.74) May Not Be Comparable To $(0.35) Estimate, Sales $166.80M Miss $196.49M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Apellis Pharmaceuticals will report an earnings per share (EPS) of $-0.34.
The announcement from Apellis Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Apellis Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.40</td>
<td>-0.30</td>
<td>-0.32</td>
<td>-0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.29</td>
<td>-0.46</td>
<td>-0.28</td>
<td>-0.54</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746547279_0.png" alt="eps graph" />
<h3>Performance of Apellis Pharmaceuticals Shares</h3>
Shares of Apellis Pharmaceuticals were trading at $19.98 as of May 05. Over the last 52-week period, shares are down 53.25%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/APLS/earnings">To track all earnings releases for Apellis Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Apellis Pharmaceuticals's Earnings Outlook

During the last three months, 9 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.89, a high estimate of $57.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 0.36% increase from the previous average price target of $38.75.
<img src="https://www.benzinga.com/files/images/story/2025/1745931741_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Apellis Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Eliana Merle &#x7C;Cantor Fitzgerald &#x7C;Announces &#x7C;Overweight &#x7C; $44.00&#x7C;- &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $21.00&#x7C;$24.00 &#x7C; 
&#x7C;Greg Harrison &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Perform &#x7C; $31.00&#x7C;$30.00 &#x7C; 
&#x7C;Anupam Rama &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $54.00&#x7C;$50.00 &#x7C; 
&#x7C;Luca Issi &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $25.00&#x7C;$26.00 &#x7C; 
&#x7C;Salveen Richter &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Neutral &#x7C; $32.00&#x7C;$36.00 &#x7C; 
&#x7C;Laura Chico &#x7C;Wedbush &#x7C;Lowers &#x7C;Neutral &#x7C; $29.00&#x7C;$30.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C; 
&#x7C;Douglas Tsao &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $57.00&#x7C;$57.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Apellis Pharmaceuticals's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Apellis Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Breaking Down Apellis Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.19% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of -17.11%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.61%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.07%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 2.06. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals

Cantor Fitzgerald analyst Eliana Merle initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Overweight rating and announces Price Target of $44.

Initiation

Cantor Fitzgerald Initiates Coverage On Apellis Pharmaceuticals with Overweight Rating, Announces Price Target of $44

RBC Capital analyst Luca Issi maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and lowers the price target from $24 to $21.

RBC Capital Maintains Sector Perform on Apellis Pharmaceuticals, Lowers Price Target to $21

Scotiabank analyst Greg Harrison maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Sector Perform and raises the price target from $30 to $31.

Scotiabank Maintains Sector Perform on Apellis Pharmaceuticals, Raises Price Target to $31

The U.S. Food and Drug Administration (FDA) on Tuesday accepted and granted Priority Review designation to Apellis Pharmaceuticals, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) supplemental New Drug Application (sNDA) for Empaveli (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative <a href="https://www.benzinga.com/general/health-care">glomerulonephritis (IC-MPGN)</a>.
C3G and primary IC-MPGN are rare kidney diseases. Excessive C3c deposits are a key marker of disease activity, which can lead to kidney inflammation, damage, and failure. The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/03/44383078/jp-morgan-cut-apellis-price-forecasts-cites-longer-peak-sales-timing-for-syfovre" target="_blank" rel="noreferrer noopener">JPMorgan Cut Apellis&#8217; Price Forecasts, Cites Longer Peak Sales Timing For Syfovre</a>
The Prescription Drug User Fee Act (PDUFA) target action <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44581423/apellis-announces-fda-acceptance-and-priority-review-of-the-supplemental-new-drug-application-for-" rel="noreferrer noopener">date is July 28, 2025</a>.
The supplemental application submission supported by Phase 3 VALIANT results at Week 26:
<ul>
<li>Proteinuria reduction:&nbsp;The study met its primary endpoint, demonstrating a statistically significant 68% (p&lt;0.0001) proteinuria reduction in Empaveli-treated patients compared to placebo.</li>
<li>Stabilization of kidney function:&nbsp;Empaveli-treated patients achieved stabilization of kidney function (nominal p=0.03) as measured by eGFR.</li>
<li>Reduction of C3c staining:&nbsp;A substantial proportion of Empaveli-treated patients achieved a reduction in C3c staining intensity (nominal p&lt;0.0001).&nbsp;71% of Empaveli-treated patients showed complete clearance of C3c staining compared to placebo.</li>
</ul>
Empaveli showed favorable safety and tolerability, which is consistent with its established profile.
William Blair writes, &#8220;We believe the recent approval of Fabhalta (iptacopan) for the treatment of adults with C3G bodes well for an approval of Empaveli given it demonstrated what we believe is best-in-class data and did so in a broader population that included adolescents, patients with IC-MPGN, and post-transplant patients, which should support a broader label and larger addressable market.&#8221;
In March, the FDA approved Novartis AG&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) oral Fabhalta&nbsp;(iptacopan) for adults with C3 glomerulopathy (C3G) to reduce proteinuria (protein in the urine), making it the first and only treatment&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44439352/fda-approves-expanded-use-of-novartis-rare-disease-drug-as-only-treatment-for-rare-type-of-kidney-disease" rel="noreferrer noopener">approved for this condition</a>.
Price Action: APLS stock is up 8.05% at $23.63&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44586220/jones-soda-reports-wider-quarterly-loss-driven-by-lower-sales-volume-inventory-write-off" target="_blank" rel="noreferrer noopener">Jones Soda Reports Wider Quarterly Loss Driven By Lower Sales Volume, Inventory Write-Off</a></li>
</ul>
Image: Shutterstock

Analyst Color

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Apellis Pharmaceuticals shares are trading higher after the company announced FDA acceptance, priority review of sNDA for EMPAVELI.

Apellis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the supplemental New Drug Application (sNDA) for EMPAVELI&#xAE; (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases. The Prescription Drug User Fee Act (PDUFA) target action date is July 28, 2025.

Government

Regulations

Apellis' EMPAVELI Gets Fast-Tracked by FDA for C3G and IC-MPGN Treatment with Action Date Set for July 2025

Press Releases

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

Management

Apellis Announces Craig Wheeler to Join the Board of Directors

Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results

Comments

Apellis Pharmaceuticals

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO